No Data
Craig-Hallum Maintains CareDx(CDNA.US) With Buy Rating
Craig-Hallum analyst William Bonello maintains $CareDx(CDNA.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 75.0% and a total average return of 39.3% over the past
Landmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients
Surveillance Monitoring with Both AlloSure Kidney and the AlloView AI-Enabled Risk Prediction Model Improves the Detection of All Types of Allograft Rejection AlloSure Kidney Detected Subclinical Rejection in
CaredX Inc.: Jefferies underwrites under a purchase rating assumption; target share price is $17 to $12
CaredX Inc.: Jefferies underwrites under a purchase rating assumption; target share price is $17 to $12
Express News | CareDx Inc : Jefferies Assumes Coverage With Buy Rating; Price Target $17 Vs $12
Decoding 6 Analyst Evaluations For CareDx
Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on CareDx (NASDAQ:CDNA) in the last three months.The table below summarizes their recent ratings, s
HC Wainwright & Co. : Reiterates CaredX (CDNA.US) neutral rating.
HC Wainwright & Co. : Reiterates CaredX (CDNA.US) neutral rating.